In a study presented at MDS 2021, researchers assessed the progression of spinocerebellar ataxias type 1, 2, 3, and 6, an autosomal dominantly inheritance, to identify factors that influence the transition to higher disability.
Researchers shared their findings on the cerebrospinal fluid profile of patients with fragile X-associated tremor/ataxia syndrome and potential biomarkers.
By studying the progression of symptoms in patients with Friedreich ataxia, researchers may help inform clinical trial designs and allow clinicians to better tailor therapies for this population.
Neurologic manifestations are common in COVID-19, occurring in 82.3 percent of hospitalized patients.
The FDA has granted Orphan Drug designation to CAD-1883 (Cadent Therapeutics), an investigational treatment for spinocerebellar ataxia (SCA).
Exome capture with a targeted analysis may allow for a molecular level diagnosis in patients with cerebellar ataxia.
